

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit	: 1644	Customer No.: 35811
Examiner	: Ronald B. Schwadron	
Serial No.	: 09/155,514	Docket: 1102-98
Filed	: November 17, 1998	
Inventors	: Mie Kainoh	
	: Toshiaki Tanaka	Confirmation No.: 8751
Title	: CHIMERIC PROTEINS, THEIR	
	: HETERODIMER COMPLEXES, AND	
	: PLATELET SUBSTITUTES	Date: January 21, 2005

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

Certificate of Mailing

For

Post Card

Amendment Transmittal Letter, in duplicate
Response to Office Communication and Amendment
Paper copy of sequence listing


Statement to Support Filing and Submission in Accordance with 37 C.F.R. §§1.821-1.825
Computer readable form of sequence listing
Copy of Notice to Comply

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to **Mail Stop Amendment**, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date appearing below.

Name of Applicant, Assignee, Applicant's Attorney
or Registered Representative:

DLA Piper Rudnick Gray Cary US LLP
Customer No. 035811

By: Paul Carano
Date: January 21, 2005



Attorney Docket No.: 1102-98

1644
JFW

In re Application of Mie-Kainoh, et al.

Serial No.: 09/155,514

Filed: November 17, 1998

For: CHIMERIC PROTEINS, THEIR HETERODIMER COMPLEXES AND PLATELET
SUBSTITUTES

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted herewith is an Amendment in the above-identified application.

- ☐ Small entity status of this application under 37 CFR §1.9 and §1.27 has been established.
- ☐ A verified statement to establish small entity status under 37 CFR §1.9 and §1.27 is enclosed.
- ☒ No additional fee is required.

The fee has been calculated as shown below:

(Col. 1)

(Col. 2) (Col. 3)

SMALL ENTITY

OTHER THAN
SMALL ENTITY

	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PRE- VIOUSLY PAID FOR	PRESENT EXTRA
TOTAL	* 7	-	** 64=	0
INDEP.	* 1	-	** 6=	0
Application Size Fee				
First Presentation of Multiple Dependent Claim				

RATE	ADD'L FEE
x 25 =	\$
X 100 =	\$
	\$
+180=	\$

OR

RATE	ADD'L FEE
x50 =	\$
x 200 =	\$
x250=	\$
+360=	\$

TOTAL ADDITIONAL FEE

\$0.00

OR

\$ _____

- * If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.
- ** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.
- *** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (Total or Independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment or the number of claims originally filed.

☐ Please charge my Deposit Account No. 50-2719 in the amount of \$_____.
A duplicate copy of this sheet is enclosed.


☐ A check in the amount of \$_____ is attached.

☒ The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 50-2719. A duplicate copy of this sheet is enclosed.

☒ Any filing fees under 37 CFR §1.16 for the presentation of extra claims.

☒ Any patent application processing fees under 37 CFR §1.17 with the exception of the Issue Fee which we intend to pay by check.

Respectfully submitted,



Paul Carango
Reg. No. 42,386
Attorney for Applicant(s)

PC:rb
(215) 656-3320



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit	: 1644	Customer No.: 035811
Examiner	: Ronald B. Schwadron	
Serial No.	: 09/155,514	
Filed	: November 17, 1998	
Inventors	: Mie Kainoh	Docket No.: 1102-98
	: Toshiaki Tanaka	
Title	: CHIMERIC PROTEINS, THEIR	Confirmation No.: 8751
	: HETERODIMER COMPLEXES, AND	
	: PLATELET SUBSTITUTES	Date: January 21, 2005

RESPONSE TO OFFICE COMMUNICATION AND AMENDMENT

Mail Stop Amendment

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

This is submitted in response to the Office Communication dated December 21, 2004.

Amendments to the Specification begin on pg. 2 of this paper.

Remarks begin on pg. 3 of this paper.